Cozaar and Thrombophlebitis superficial - a phase IV clinical study of FDA data

Summary:

Thrombophlebitis superficial is reported as a side effect among people who take Cozaar (losartan potassium), especially for people who are male, 60+ old, also take Lasix, and have Deep venous thrombosis.

The phase IV clinical study analyzes which people have Thrombophlebitis superficial when taking Cozaar. It is created by eHealthMe based on reports of 43,582 people who have side effects when taking Cozaar from the FDA, and is updated regularly.

What is Cozaar?

Cozaar has active ingredients of losartan potassium. It is often used in high blood pressure. eHealthMe is studying from 45,124 Cozaar users. Check the latest studies of Cozaar.

What is Thrombophlebitis superficial?

Thrombophlebitis superficial (swelling (inflammation) of a superficial vein caused by a blood clot) is found to be associated with 516 drugs and 700 conditions by eHealthMe. Check the latest studies of Thrombophlebitis superficial.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 27, 2026

43,582 people reported to have side effects when taking Cozaar.
Among them, 17 people (0.04%) have Thrombophlebitis superficial.

Could Cozaar cause Thrombophlebitis superficial?

Among these 17 people:

What is the gender of people who have Thrombophlebitis superficial when taking Cozaar? *

  • female: 47.06 %
  • male: 52.94 %

What is the age of people who have Thrombophlebitis superficial when taking Cozaar? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 12.5 %
  • 30-39: 0.0 %
  • 40-49: 31.25 %
  • 50-59: 12.5 %
  • 60+: 43.75 %

What are other drugs people take besides Cozaar? *

  1. Lasix: 5 people, 29.41%
  2. Humalog: 4 people, 23.53%
  3. Synthroid: 4 people, 23.53%
  4. Klonopin: 3 people, 17.65%
  5. Cellcept: 3 people, 17.65%
  6. Restoril: 3 people, 17.65%
  7. Skelaxin: 3 people, 17.65%
  8. Remeron: 3 people, 17.65%
  9. Pepcid: 3 people, 17.65%
  10. Ativan: 3 people, 17.65%

What are other side effects people have besides Thrombophlebitis superficial? *

  1. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 7 people, 41.18%
  2. Oedema Peripheral (superficial swelling): 4 people, 23.53%
  3. Thrombocytopenia (decrease of platelets in blood): 4 people, 23.53%
  4. Wound Dehiscence (a surgical incision reopens either internally or externally): 3 people, 17.65%
  5. Head Injury: 3 people, 17.65%
  6. Neuroleptic Malignant Syndrome (a life-threatening neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic agents): 3 people, 17.65%
  7. Neck Pain: 3 people, 17.65%
  8. Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 3 people, 17.65%
  9. Leukocytosis (increased white blood cells): 3 people, 17.65%
  10. Joint Injury: 3 people, 17.65%

What are the existing conditions these people have? *

  1. Bipolar Disorder (mood disorder): 3 people, 17.65%
  2. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 3 people, 17.65%
  3. Hypersensitivity: 2 people, 11.76%
  4. Stress And Anxiety: 1 person, 5.88%
  5. Allergic Rhinitis: 1 person, 5.88%
  6. Angioedema (rapid swelling of the dermis): 1 person, 5.88%
  7. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 5.88%
  8. Depression: 1 person, 5.88%
  9. Diabetes: 1 person, 5.88%
  10. Embolism Venous (embolus may pass into the arterial system): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Cozaar and have Thrombophlebitis superficial?

- Check whether Thrombophlebitis superficial is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cozaar:

Thrombophlebitis superficial treatments and more:

How severe was Thrombophlebitis superficial and when was it recovered:

Expand to all the drugs that have ingredients of losartan potassium:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cozaar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thrombophlebitis superficial:

Browse all the conditions that are associated with Thrombophlebitis superficial:

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on losartan potassium (the active ingredients of Cozaar) and Cozaar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: